128 related articles for article (PubMed ID: 38654611)
21. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa T; Yamamura R; Ohta K; Kaneko H; Imada K; Nakaya A; Fuchida SI; Shibayama H; Matsuda M; Shimazu Y; Adachi Y; Kosugi S; Uchiyama H; Tanaka H; Hanamoto H; Shimura Y; Kanda J; Onda Y; Uoshima N; Yagi H; Yoshihara S; Hino M; Shimazaki C; Takaori-Kondo A; Kuroda J; Matsumura I; Kanakura Y; Nomura S
Eur J Haematol; 2021 Apr; 106(4):555-562. PubMed ID: 33476404
[TBL] [Abstract][Full Text] [Related]
22. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Richardson PG; Kumar SK; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Gimsing P; Garderet L; Touzeau C; Buadi FK; Laubach JP; Cavo M; Darif M; Labotka R; Berg D; Moreau P
J Clin Oncol; 2021 Aug; 39(22):2430-2442. PubMed ID: 34111952
[TBL] [Abstract][Full Text] [Related]
23. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Maouche N; Kishore B; Jenner MW; Boyd K; Bhatti Z; Bird SA; Chander G; Robinson R; Vallance GD; Offer M; Kothari J; Peniket A; Aitchison R; Dungarwalla M; Collings F; Bygrave C; Ramasamy K
Leuk Lymphoma; 2021 Jun; 62(6):1396-1404. PubMed ID: 33356703
[TBL] [Abstract][Full Text] [Related]
24. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
25. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey.
Bakırtaş M; Dal MS; Yiğenoğlu TN; Giden AO; Serin I; Başcı S; Kalpakci Y; Korkmaz S; Ekinci O; Albayrak M; Basturk A; Ozatli D; Dogu MH; Hacıbekiroglu T; Çakar MK; Ulas T; Miskioglu M; Gulturk E; Eser B; Altuntas F
J Chemother; 2023 Oct; 35(6):563-569. PubMed ID: 37211906
[TBL] [Abstract][Full Text] [Related]
26. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
[TBL] [Abstract][Full Text] [Related]
27. Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Sokol J; Guman T; Chudej J; Hlebaskova M; Stecova N; Valekova L; Kucerikova M; Stasko J
Ann Hematol; 2022 Jan; 101(1):81-89. PubMed ID: 34550463
[TBL] [Abstract][Full Text] [Related]
28. [Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime].
Hardi A; Varga G; Nagy Z; Kosztolányi S; Váróczy L; Plander M; Schneider T; Demeter J; Alizadeh H; Illés Á; Masszi T; Mikala G
Orv Hetil; 2021 Sep; 162(36):1451-1458. PubMed ID: 34482291
[TBL] [Abstract][Full Text] [Related]
29. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S
Blood Cancer J; 2022 Jan; 12(1):9. PubMed ID: 35075109
[TBL] [Abstract][Full Text] [Related]
30. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
Szudy-Szczyrek A; Chocholska S; Bachanek-Mitura O; Czabak O; Mlak R; Szczyrek M; Muzyka-Kasietczuk J; Hus M
Ann Agric Environ Med; 2022 Mar; 29(1):103-109. PubMed ID: 35352912
[TBL] [Abstract][Full Text] [Related]
32. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Voorhees PM; Suman VJ; Tuchman SA; Laubach JP; Hassoun H; Efebera YA; Mulkey F; Bova-Solem M; Santo K; Carlisle D; McCarthy PL; Richardson PG
Am J Hematol; 2021 Dec; 96(12):1595-1603. PubMed ID: 34559902
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
[TBL] [Abstract][Full Text] [Related]
34. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from
Duarte PJ; Schutz NP; Ochoa P; Yantorno S; Orlando S; Lopresti S; Zabaljauregui S; Aizpurua F; Shanley C; Giannini E; Garate G; Foncuberta C; Milone J; Riveros D; Fantl D
Expert Rev Hematol; 2021 Mar; 14(3):315-322. PubMed ID: 33541156
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
36. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
Mateos MV; Engelhardt M; Leleu X; Mesa MG; Cavo M; Dimopoulos M; Bianco M; Merlo GM; Porte C; Richardson PG; Moreau P
Eur J Haematol; 2024 May; ():. PubMed ID: 38693052
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Terpos E; Ntanasis-Stathopoulos I; Gavriatopoulou M; Katodritou E; Hatjiharissi E; Malandrakis P; Verrou E; Golfinopoulos S; Migkou M; Manousou K; Delimpasi S; Symeonidis A; Kastritis E; Dimopoulos MA
Am J Hematol; 2024 Mar; 99(3):396-407. PubMed ID: 38298023
[TBL] [Abstract][Full Text] [Related]
38. [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].
Yang Y; Xia ZJ; Zhang WH; Fu CC; Bao L; Chen B; Ding KY; Wang SL; Luo J; Li BZ; Hua LM; Yang W; Zhou X; Wang L; Xu TH; Wang WD; Wu GL; Huang Y; Li J; Liu P
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):628-634. PubMed ID: 34547867
[No Abstract] [Full Text] [Related]
39. New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.
Richardson PG; Kumar S; Laubach JP; Paba-Prada C; Gupta N; Berg D; van de Velde H; Moreau P
J Blood Med; 2017; 8():107-121. PubMed ID: 28860887
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.
Nadeem O; Aranha MP; Redd R; Timonian M; Magidson S; Lightbody ED; Alberge JB; Bertamini L; Dutta AK; El-Khoury H; Bustoros M; Laubach JP; Bianchi G; O'Donnell E; Wu T; Tsuji J; Anderson K; Getz G; Trippa L; Richardson PG; Sklavenitis-Pistofidis R; Ghobrial IM
medRxiv; 2024 Apr; ():. PubMed ID: 38699307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
